Find comprehensive information on Intraductal Papillary Mucinous Neoplasm IPMN including clinical documentation tips medical coding guidelines and healthcare resources. Learn about IPMN diagnosis treatment options and prognosis. Explore relevant medical terminology such as main duct IPMN branch duct IPMN and IPMN with high-grade dysplasia. This resource provides valuable insights for healthcare professionals involved in the diagnosis management and coding of IPMN cases.
Also known as
Intraductal papillary mucinous neoplasm
Benign or malignant tumor of the pancreatic ducts.
Malignant neoplasm of pancreas
Cancer originating in the pancreas, including various types.
Benign neoplasm of pancreas
Non-cancerous tumor of the pancreas, not specified elsewhere.
Secondary malignant neoplasm of pancreas
Cancer that has spread to the pancreas from another primary site.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the IPMN invasive?
When to use each related code
| Description |
|---|
| Intraductal papillary mucinous neoplasm |
| Pancreatic cyst |
| Mucinous cystic neoplasm |
Coding IPMN requires specific histology documentation (e.g., adenoma, borderline, carcinoma in situ, invasive) for accurate code assignment and proper reimbursement.
Distinguishing main duct IPMN from branch duct IPMN is crucial for accurate coding, as it impacts prognosis and treatment. Documentation must clearly identify the location.
Precise documentation of invasion status (e.g., in situ, invasive) is critical for proper IPMN coding and staging, influencing treatment and resource allocation.
Patient presents with symptoms concerning for intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Presenting complaints include abdominal pain, jaundice, weight loss, and new-onset diabetes. Patient denies history of pancreatitis. Physical examination reveals mild epigastric tenderness. Differential diagnosis includes pancreatic cyst, pseudocyst, cystic neoplasm, and pancreatic adenocarcinoma. Imaging studies, including abdominal ultrasound, CT scan of the abdomen with pancreatic protocol, and MRI with MRCP, were ordered to evaluate the pancreatic lesion. Imaging findings demonstrate a cystic lesion within the pancreatic duct consistent with IPMN. The lesion measures [measurement] cm and demonstrates [description of features, e.g., main duct involvement, branch duct involvement, mural nodules, etc.]. CA 19-9 levels were obtained and are [result]. EUS with fine-needle aspiration (FNA) was performed for cytological evaluation and to obtain fluid for CEA analysis. Cytology revealed [cytology results]. CEA level in the cyst fluid was [result]. Based on the clinical presentation, imaging characteristics, and cytology results, the diagnosis of IPMN is favored. The patient was counseled regarding the potential for malignant transformation and the need for surgical resection versus surveillance. Risks and benefits of surgical resection, including distal pancreatectomy versus Whipple procedure, were discussed. The patient was referred to surgical oncology for further evaluation and management. The patient understands the diagnosis, treatment options, and the importance of follow-up. ICD-10 code D13.7 and appropriate CPT codes for the procedures performed will be documented.